Table 8

DDI definitions in corpus
DDI relationship C1 C2 C3** C4**
IN VIVO STUDY
DDI Yes Yes The PK parameter with the highest priority* must satisfy p-value <0.05 and FC > 1.50 or FC < 0.67 Significant, obviously, markedly, greatly, pronouncedly and etc.
Ambiguous DDI (ADDI) The PK parameter with the highest priority* in the conditions of p-value <0.05 but 0.67 < FC < 1.50; or FC >1.50 or FC <0.67, but p-value > 0.05. Modestly, moderately, probably, may, might, and etc.
Non-DDI (NDDI) The PK parameter with the highest priority*are in the condition of p-value > 0.05 and 0.67 < FC < 1.50 Minor significance, slightly, little or negligible effect, doesn’t interact etc.
IN VITRO STUDY
DDI Yes Yes (0< Ki < 10 or 0< EC50 < 10 microM, and p-value <0.05) Significant, obviously, markedly, greatly, pronouncedly and etc.
DEI
Ambiguous DDI (ADDI) (10 < Ki < 100 or 10 < EC50 < 100 microM, and p-value <0.05 or vice versa) Modestly, moderately, probably, may, might, and etc.
Ambiguous DEI (ADEI)
Non-DDI (NDDI) (Ki > 100 microM or EC50 > 100 microM, and p-value >0.05) Minor significance, slightly, little or negligible effect, doesn’t interact etc.
Non-DEI (NDEI)

Note:

C1: At least one drug or enzyme name has to be contained in the sentence.

C2: Need to label the drug name if it is not from the same sentence.

C3: PK-parameter and value dependent.

C4: Significance statement.

*Priority issue: When C3 and C4 occur and conflict, C3 dominates the sentence.**For the priority of PK parameters: AUC > CL > t1/2 > Cmax;; the priority of in vitro PK parameters: Ki>IC50.

Wu et al.

Wu et al. BMC Bioinformatics 2013 14:35   doi:10.1186/1471-2105-14-35

Open Data